Celiac disease is characterized as an autoimune disorder, and the trigger is gluten delivered into the body in a meal. The main purpose of the study was the issues about gluten enteropaty in East Slovakia, based on special scientific and foreign literature which was avaliable, also there are characteristics about digestion, celiac disease and gluten, critical factors and also premiss beginners of celiac disease. The research, which is discussed at the end of the thesis, was conducted in East Slovakia, namely in the gastroenterologic ambulance in the Humenné town. The above-mentioned research brought us information about the current position of celiac disease between different ages in the Humenné region. Our main aim was to find out whether there is any significant correlation between the age and risk of involvement of celiac disease.
{"title":"The gluten enteropathy in East Slovakia","authors":"Gabriela Harvanová, S. Duranková, A. Csanády","doi":"10.5114/pja.2021.106683","DOIUrl":"https://doi.org/10.5114/pja.2021.106683","url":null,"abstract":"Celiac disease is characterized as an autoimune disorder, and the trigger is gluten delivered into the body in a meal. The main purpose of the study was the issues about gluten enteropaty in East Slovakia, based on special scientific and foreign literature which was avaliable, also there are characteristics about digestion, celiac disease and gluten, critical factors and also premiss beginners of celiac disease. The research, which is discussed at the end of the thesis, was conducted in East Slovakia, namely in the gastroenterologic ambulance in the Humenné town. The above-mentioned research brought us information about the current position of celiac disease between different ages in the Humenné region. Our main aim was to find out whether there is any significant correlation between the age and risk of involvement of celiac disease.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The International Classification of Diseases (ICD) was implemented by the WHO to classify diseases and medical procedures. It is updated regularly, usually every 10 years. The ICD is widely used for the refund purposes and funds deployment in the healthcare system. Due to the rapid development of medicine, the need for detailed recording of new clinical situations increased. The current version of the ICD-10 began to lose its relevance. In 2011 WHO began to work on the new version of ICD. The latest version of ICD-11 will be effective from January 1, 2022. In the article we present the differences between the current ICD-10 and ICD-11 classification, updated rules for classifying and characterizing diseases and describe the newly created chapter on allergic diseases.
{"title":"Categorization of allergic diseases in the new version of International Classification of Diseases ICD-11","authors":"Lesia Rozłucka, Olga Branicka, R. Gawlik","doi":"10.5114/pja.2021.111799","DOIUrl":"https://doi.org/10.5114/pja.2021.111799","url":null,"abstract":"The International Classification of Diseases (ICD) was implemented by the WHO to classify diseases and medical procedures. It is updated regularly, usually every 10 years. The ICD is widely used for the refund purposes and funds deployment in the healthcare system. Due to the rapid development of medicine, the need for detailed recording of new clinical situations increased. The current version of the ICD-10 began to lose its relevance. In 2011 WHO began to work on the new version of ICD. The latest version of ICD-11 will be effective from January 1, 2022. In the article we present the differences between the current ICD-10 and ICD-11 classification, updated rules for classifying and characterizing diseases and describe the newly created chapter on allergic diseases.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70480042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is con-ducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.
过敏原免疫疗法(AIT)已被证明对ige依赖性呼吸系统疾病有效。当AIT持续进行3年，它可以在停止治疗后获得长期的临床益处。虽然多项研究证实了AIT的高疗效，但仍有一些患者对这种治疗没有反应(“无反应”)或发现其结果不令人满意(“不良反应”)。什么因素可能导致AIT治疗不成功或者治疗效果不理想?如何预测AIT治疗失败?生物标志物能促进预测吗?如何识别治疗失败的病人?本文阐述了AIT失败的原因:对潜在过敏疾病的错误诊断，临床上对AIT的非重要过敏原的选择，对主要过敏原的不敏感以及AIT的不良执行。关于AIT的成功或失败，另外要解决的问题是分子谱的异质性和对临床重要分子(如Der p 23)的敏感性。
{"title":"Immunotherapy – the causes of sub-optimal efficacy in inhaled allergies","authors":"M. Nittner-Marszalska","doi":"10.5114/PJA.2021.104618","DOIUrl":"https://doi.org/10.5114/PJA.2021.104618","url":null,"abstract":"Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is con-ducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients' deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.
{"title":"Safety of biological treatment of severe asthma during the COVID-19 pandemic","authors":"Dorota Nawarycz, R. Pawliczak","doi":"10.5114/pja.2021.109381","DOIUrl":"https://doi.org/10.5114/pja.2021.109381","url":null,"abstract":"COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients' deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amelia Kierasińska, Damian Ciunowicz, Marta Węgierska, E. Stoczyńska-Fidelus, P. Rieske
Recently, there has been a breakthrough in immunotherapy. The development of the advanced therapy medicinal product (ATMP) is a striking example of that. Chimeric antigen receptors T cell therapy (CAR-T therapy) is the result of cooperation between biotechnologists, oncologists and immunologists. This article deals with the issues related to the development of CAR-T technology. The basics of CAR-T design and the mechanism of this therapy action are discussed. Its successes were indicated mainly in the treatment of patients with leukemias and lymphomas. EGFRvIII as an exemplary target for the therapy of solid tumors is described. However, it was pointed out what difficulties the therapy against mutated variant of epidermal growth factor receptor EGFRvIII-positive cells encounters. The growing importance of PSMA and GD2 as targets for CAR-T was also pointed out. New trends in this technology, such as the next generations of CAR-T and development of CAR-M, were noticed. Finally, the potential of CAR-T treatment in non-cancerous diseases, such as cardiac diseases, allergies or infectious diseases, including COVID-19, was characterized.
{"title":"CAR-T therapy in oncology and other fields of medicine","authors":"Amelia Kierasińska, Damian Ciunowicz, Marta Węgierska, E. Stoczyńska-Fidelus, P. Rieske","doi":"10.5114/pja.2021.106685","DOIUrl":"https://doi.org/10.5114/pja.2021.106685","url":null,"abstract":"Recently, there has been a breakthrough in immunotherapy. The development of the advanced therapy medicinal product (ATMP) is a striking example of that. Chimeric antigen receptors T cell therapy (CAR-T therapy) is the result of cooperation between biotechnologists, oncologists and immunologists. This article deals with the issues related to the development of CAR-T technology. The basics of CAR-T design and the mechanism of this therapy action are discussed. Its successes were indicated mainly in the treatment of patients with leukemias and lymphomas. EGFRvIII as an exemplary target for the therapy of solid tumors is described. However, it was pointed out what difficulties the therapy against mutated variant of epidermal growth factor receptor EGFRvIII-positive cells encounters. The growing importance of PSMA and GD2 as targets for CAR-T was also pointed out. New trends in this technology, such as the next generations of CAR-T and development of CAR-M, were noticed. Finally, the potential of CAR-T treatment in non-cancerous diseases, such as cardiac diseases, allergies or infectious diseases, including COVID-19, was characterized.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"17th International Academy of Dermatology and Allergology (17ADA), Gdynia 2021","authors":"E. Grubska-Suchanek, R. Nowicki","doi":"10.5114/PJA.2021.104657","DOIUrl":"https://doi.org/10.5114/PJA.2021.104657","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. U. Severcan, Nilgun Erdonmez Karslioglu, I. Bostanci
{"title":"Do parents of children with allergic diseases need psychological support?","authors":"E. U. Severcan, Nilgun Erdonmez Karslioglu, I. Bostanci","doi":"10.5114/PJA.2021.106689","DOIUrl":"https://doi.org/10.5114/PJA.2021.106689","url":null,"abstract":"","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
szczególną rolę. abSTracT Techniques such as TALEN, CRISPR-CAS9 or traktuje komórkę oraz jej elementy, np. białka, w sposób podobny do tego, którego używa się przy opracowywaniu układów scalonych w elektronice. PE polega na działaniu dwóch chimer, każdej złożonej z trzech podjednostek. Trzy elementy białkowe tworzą jedną chimerę (nikaza, odwrotna editing systems in therapy. Immune system cells also seem to be particularly suitable as starting points for the creation of completely new cell types thanks to synthetic biology, in which genome editing techniques play an important role. All this makes CRISPR-CAS9 or PE more and more interesting for immunologists. The article discusses the basics of these techniques and explains the reasons for their imperfections.
{"title":"Genome editing tools to modify immune cells","authors":"E. Stoczyńska-Fidelus, P. Rieske","doi":"10.5114/pja.2021.111800","DOIUrl":"https://doi.org/10.5114/pja.2021.111800","url":null,"abstract":"szczególną rolę. abSTracT Techniques such as TALEN, CRISPR-CAS9 or traktuje komórkę oraz jej elementy, np. białka, w sposób podobny do tego, którego używa się przy opracowywaniu układów scalonych w elektronice. PE polega na działaniu dwóch chimer, każdej złożonej z trzech podjednostek. Trzy elementy białkowe tworzą jedną chimerę (nikaza, odwrotna editing systems in therapy. Immune system cells also seem to be particularly suitable as starting points for the creation of completely new cell types thanks to synthetic biology, in which genome editing techniques play an important role. All this makes CRISPR-CAS9 or PE more and more interesting for immunologists. The article discusses the basics of these techniques and explains the reasons for their imperfections.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70480102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katarzyna Waligóra-Dziwak, M. Woźniak, D. Jenerowicz, Z. Adamski, M. Czarnecka-Operacz
Hereditary angioedema (HAE) is a genetically determined disease characterized by recurrent episodes of subcu-taneous or submucosal tissue oedema. Failure to respond to the classical treatment of angioedema with antihista-mines, glucocorticosteroids as well as adrenaline is highly characteristic for HAE. Three main types of HAE have been described: type I – associated with hereditary reduction of C1 esterase inhibitor plasma concentration, type II – associated with its dysfunction and type III with both C1 inhibitor concentration and activity being within the normal range. We present a case report of a 16-year-old female patient with chronic spontaneous angioedema with normal activity and concentration of C1 inhibitor as well as an updated review of the current knowledge concerning pathophysiology, clinical genetic HAE type
{"title":"Hereditary angioedema type III – case report","authors":"Katarzyna Waligóra-Dziwak, M. Woźniak, D. Jenerowicz, Z. Adamski, M. Czarnecka-Operacz","doi":"10.5114/PJA.2021.104656","DOIUrl":"https://doi.org/10.5114/PJA.2021.104656","url":null,"abstract":"Hereditary angioedema (HAE) is a genetically determined disease characterized by recurrent episodes of subcu-taneous or submucosal tissue oedema. Failure to respond to the classical treatment of angioedema with antihista-mines, glucocorticosteroids as well as adrenaline is highly characteristic for HAE. Three main types of HAE have been described: type I – associated with hereditary reduction of C1 esterase inhibitor plasma concentration, type II – associated with its dysfunction and type III with both C1 inhibitor concentration and activity being within the normal range. We present a case report of a 16-year-old female patient with chronic spontaneous angioedema with normal activity and concentration of C1 inhibitor as well as an updated review of the current knowledge concerning pathophysiology, clinical genetic HAE type","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70478724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Allergic sensitization to aeroallergen (atmospheric pollen and fungal spores) is the most common seasonal allergy trigger. The main reason for that study is unexpected skin prick test results obtained in our dermatology department. For that reason, we would like to check whether the consequences depend on cross-reactivity or aeroallergen invasion. Aim: The purpose of the present study is to determine the pollen types, including the amount and concentration of the native and invasive pollen in the Çanakkale Region during the spring and summer periods. The main reason for that study is unexpected skin prick test results obtained in our dermatology department. For that reason, we would like to check whether the consequences depend on cross-reactivity or aeroallergen invasion. Material and methods: The pollen monitoring station was placed in the Çanakkale Central Public Park. The sampling was performed by a Durham trap based on the gravimetric method. The slide was replaced with a new one every week and evaluated by 10× ocular and 40× apochromatic lenses. Results: The primary pollen producers were the following arboreal plants: Pinus sp. (65.0%), Quercus sp. (9.37%), Platanus sp. (4.29%), Moraceae (3.87%), Oleaceae (2.71%). The pollen distribution of herbaceous plants and bushes were determined as Poaceae (4.34%), Chenopodiaceae (1.99%), Plantago sp. (1.97%) and Xanthium sp. (1.35%). In addition to our current knowledge, Ambrosia pollens’ first record was found with a ratio of 0.22% in the Çanakkale atmosphere. These invasive plants have most probably entered the atmosphere with long-distance transport. Conclusions: Aerobiological monitoring is essential to determine allergen variety and concentrations to find a cure against pollinosis. The health professionals should apply a skin prick test against a significant allergen, i.e. Ambrosia pollens even if there is no previous report in the region. The authors also advised clinicians to be aware of pollen invasion to ensure that patients do not have false-negative results.
{"title":"Importance of aerobiological monitoring to determine artemisia and ambrosia hypersensitivity","authors":"M. M. Cicekliyurt, M. Akkaya","doi":"10.5114/pja.2021.106688","DOIUrl":"https://doi.org/10.5114/pja.2021.106688","url":null,"abstract":"Introduction: Allergic sensitization to aeroallergen (atmospheric pollen and fungal spores) is the most common seasonal allergy trigger. The main reason for that study is unexpected skin prick test results obtained in our dermatology department. For that reason, we would like to check whether the consequences depend on cross-reactivity or aeroallergen invasion. Aim: The purpose of the present study is to determine the pollen types, including the amount and concentration of the native and invasive pollen in the Çanakkale Region during the spring and summer periods. The main reason for that study is unexpected skin prick test results obtained in our dermatology department. For that reason, we would like to check whether the consequences depend on cross-reactivity or aeroallergen invasion. Material and methods: The pollen monitoring station was placed in the Çanakkale Central Public Park. The sampling was performed by a Durham trap based on the gravimetric method. The slide was replaced with a new one every week and evaluated by 10× ocular and 40× apochromatic lenses. Results: The primary pollen producers were the following arboreal plants: Pinus sp. (65.0%), Quercus sp. (9.37%), Platanus sp. (4.29%), Moraceae (3.87%), Oleaceae (2.71%). The pollen distribution of herbaceous plants and bushes were determined as Poaceae (4.34%), Chenopodiaceae (1.99%), Plantago sp. (1.97%) and Xanthium sp. (1.35%). In addition to our current knowledge, Ambrosia pollens’ first record was found with a ratio of 0.22% in the Çanakkale atmosphere. These invasive plants have most probably entered the atmosphere with long-distance transport. Conclusions: Aerobiological monitoring is essential to determine allergen variety and concentrations to find a cure against pollinosis. The health professionals should apply a skin prick test against a significant allergen, i.e. Ambrosia pollens even if there is no previous report in the region. The authors also advised clinicians to be aware of pollen invasion to ensure that patients do not have false-negative results.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70479528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：